dichlororibofuranosylbenzimidazole has been researched along with Lymphoma in 2 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tweeten, KA | 1 |
| Molloy, GR | 1 |
| Genovese, C | 1 |
| Milcarek, C | 1 |
2 other studies available for dichlororibofuranosylbenzimidazole and Lymphoma
| Article | Year |
|---|---|
Inhibition of messenger RNA synthesis by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole without its detectable accumulation in mouse T-lymphoma cells.
Topics: Animals; Chromatography, Thin Layer; Dichlororibofuranosylbenzimidazole; Lethal Dose 50; Lymphoma; M | 1982 |
Increased half-life of mu immunoglobulin mRNA during mouse B cell development increases its abundancy.
Topics: Animals; B-Lymphocytes; Cell Differentiation; Cell Line; Cytoplasm; Dichlororibofuranosylbenzimidazo | 1990 |